Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease. The FDA's ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

"Sarepta and our partner Roche are dedicated and determined to bring this potentially transformative gene therapy to patients around the globe as rapidly as possible." Eisai and Biogen have been ...

Biogen Inc. (NASDAQ:BIIB ... which use inefficient and old passivated emitter and rear cells in the US market. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a global biotechnology company that ...

MS has received consultancy fees from Roche, Biogen, and Novartis; and honoraria and support for attending meetings from Novartis and Roche. GB has received grants from Sarepta, Roche, Novartis, ...

Contribute to shelarn123/StatEdge development by creating an account on GitHub.

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. Sarepta Therapeutics beat analysts’ revenue expectations by ...

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $170.00. The company’s ...

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Sarepta Therapeutics, Inc. (NASDAQ:SRPT). ROE or return on equity is a useful tool to assess how effectively a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility ...

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...